Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest linezolid Stories

2008-09-22 00:00:11

SAN DIEGO, Sept. 22 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the initiation of Phase 2 testing of the oral form of its second-generation oxazolidinone antibacterial drug TR-701. The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200, 300 and 400 milligrams of TR-701 in complicated skin and skin structure infections (cSSSI) for five to seven days of treatment. The study follows the recently completed two-part Phase 1 study that...

2008-09-16 09:00:53

Enanta Pharmaceuticals, a developer of small molecule anti-infective drugs, has initiated a Phase Ia study on investigational oral antibiotic EDP-322, a methicillin-resistant Staphylococcus aureus-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile. The Phase Ia, double-blind, placebo controlled study for EDP-322 announced is a single ascending dose trial in healthy volunteers. The clinical development program for EDP-322 will include the treatment...

2008-09-15 09:00:57

WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced today the initiation of a Phase 1 study on investigational oral antibiotic EDP-322, a first-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile. The clinical development program for EDP-322 will include the treatment of hospital- and community-acquired gram-positive infections, including...

2008-09-12 18:00:35

The death rate for infective endocarditis -- an infection where bacteria destroy the heart -- has increased, a British cardiologist warns. Despite medical improvements, the rate for infective endocarditis has been virtually unchanged for last 20 years, and now seems to be rising again, Dr. Bernard Prendergast of Oxford, England's John Radcliffe Hospital told a meeting of the Society for General Microbiology held at Trinity College, in Dublin, Ireland. "Now that people live so long,...

2008-09-11 06:00:33

Healthcare giant Pfizer has announced that the marketing applications for its skin infection treatment Zeven (dalbavancin) are to be withdrawn, pending another multi-center trial for the drug. This setback could cost Pfizer dearly: another trial could push the drug's launch date out to September 2010, five full years after its proposed launch date and just two years before its first patent expiry. Pfizer's decision to invest in another Phase III trial for Zeven will have been painful. There...

2008-09-10 12:00:52

Pfizer has announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the US new drug application and the European marketing authorization application. Following feedback from regulatory authorities, the company plans to conduct an additional Phase III clinical trial with dalbavancin for the treatment of adults with complicated skin and skin structure infections caused by Gram-positive...

2008-09-09 09:00:51

Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug application (NDA) and the European marketing authorization application (MAA). Following feedback from regulatory authorities, the company plans to conduct an additional Phase 3 clinical trial with dalbavancin for the treatment of adults with complicated skin and skin structure infections...

2008-09-02 09:00:43

Targanta Therapeutics Corporation (Nasdaq: TARG) today announced positive top-line results from a Phase 2 clinical trial investigating the efficacy and safety of oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI. Oritavancin is Targanta's lead antibiotic candidate targeting gram-positive organisms, including methicillin-resistant Staphylococcus aureus, or MRSA. Oritavancin, administered in a single or in an...

2008-08-30 09:00:20

By Jarzembowski, Jason A Young, Michael B * Context.-Nontuberculous mycobacteria include numerous acid- fast bacilli species, many of which have only recently been recognized as pathogenic. The diagnosis of mycobacterial disease is based on a combination of clinical features, microbiologic data, radiographic findings, and histopathologic studies. Objective.-To provide an overview of the clinical and pathologic aspects of nontuberculous mycobacteria infection, including diagnostic laboratory...

2008-08-21 09:01:14

Arpida has announced that the European Medicines Agency has accepted for review its marketing authorization application for intravenous iclaprim. Arpida is seeking approval of intravenous iclaprim in the EU for the treatment of complicated skin and soft tissue infections (cSSTI). Iclaprim is a hospital antibiotic drug candidate with potent bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and an extended range of important pathogens. The iclaprim marketing...


Latest linezolid Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »